$368.66
1.13% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US91307C1027
Symbol
UTHR

United Therapeutics Corporation Stock price

$368.66
+20.01 5.74% 1M
+95.78 35.10% 6M
+148.77 67.66% YTD
+137.56 59.52% 1Y
+168.48 84.16% 3Y
+273.32 286.68% 5Y
+237.36 180.78% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-4.23 1.13%
ISIN
US91307C1027
Symbol
UTHR
Sector
Industry

Key metrics

Market capitalization $16.46b
Enterprise Value $13.53b
P/E (TTM) P/E ratio 16.19
EV/FCF (TTM) EV/FCF 15.07
EV/Sales (TTM) EV/Sales 4.91
P/S ratio (TTM) P/S ratio 5.97
P/B ratio (TTM) P/B ratio 2.70
Revenue growth (TTM) Revenue growth 25.04%
Revenue (TTM) Revenue $2.76b
EBIT (operating result TTM) EBIT $1.28b
Free Cash Flow (TTM) Free Cash Flow $898.10m
Cash position $3.33b
EPS (TTM) EPS $22.77
P/E forward 14.90
P/S forward 5.72
EV/Sales forward 4.70
Short interest 6.79%
Show more

Is United Therapeutics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

United Therapeutics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a United Therapeutics Corporation forecast:

9x Buy
53%
6x Hold
35%
2x Sell
12%

Analyst Opinions

17 Analysts have issued a United Therapeutics Corporation forecast:

Buy
53%
Hold
35%
Sell
12%

Financial data from United Therapeutics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,756 2,756
25% 25%
100%
- Direct Costs 305 305
24% 24%
11%
2,451 2,451
25% 25%
89%
- Selling and Administrative Expenses 607 607
33% 33%
22%
- Research and Development Expense 499 499
42% 42%
18%
1,346 1,346
17% 17%
49%
- Depreciation and Amortization 67 67
26% 26%
2%
EBIT (Operating Income) EBIT 1,279 1,279
16% 16%
46%
Net Profit 1,111 1,111
23% 23%
40%

In millions USD.

Don't miss a Thing! We will send you all news about United Therapeutics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

United Therapeutics Corporation Stock News

Neutral
Investors Business Daily
4 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Seeking Alpha
11 days ago
UTHR's competitive advantages, including high returns on capital and successfully recycling of profits, support a bullish outlook. United Therapeutics' Q3 FY '24 earnings showed strong growth across major product lines, with Tyvaso, Orenitram, and Unituxin all posting significant YoY increases. My numbers project a 40% growth in earnings power for the business over the coming 2-3 years.
Neutral
Seeking Alpha
11 days ago
Despite legal challenges and exclusivity risks, United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. UTHR is innovating in organ transplantation and bioengineered organs, including xenotransplantation and ex vivo lung perfusion, which could revolutionize the market. Legal battles, particularly with Liquidia, threaten United Therapeutics' intellectual ...
More United Therapeutics Corporation News

Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Head office United States
CEO Martine Rothblatt
Employees 1,168
Founded 1996
Website www.unither.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today